Infliximab abrogates cadmium-induced testicular damage and spermiotoxicity via enhancement of steroidogenesis and suppression of inflammation and apoptosis mediators.
Animals
Antioxidants
/ metabolism
Apoptosis
/ drug effects
Cadmium
/ toxicity
Inflammation
Infliximab
/ pharmacology
Male
Oxidation-Reduction
Oxidative Stress
/ drug effects
Protective Agents
/ pharmacology
Rats
Rats, Wistar
Sperm Motility
/ drug effects
Spermatogenesis
/ drug effects
Spermatozoa
/ drug effects
Testis
/ drug effects
Testosterone
/ metabolism
Tumor Necrosis Factor-alpha
/ metabolism
Cadmium
Infliximab
Spermiotoxicity
Steroidogenesis
Testicular damage
Journal
Ecotoxicology and environmental safety
ISSN: 1090-2414
Titre abrégé: Ecotoxicol Environ Saf
Pays: Netherlands
ID NLM: 7805381
Informations de publication
Date de publication:
30 Oct 2019
30 Oct 2019
Historique:
received:
26
03
2019
revised:
22
06
2019
accepted:
27
06
2019
pubmed:
6
7
2019
medline:
11
10
2019
entrez:
6
7
2019
Statut:
ppublish
Résumé
Cadmium(Cd) is a serious environmental and occupational contaminant that represents a serious health hazard to humans and other animals. Reproductive health problems have been reported in men exposed to Cd. Testicular damage is one of the deleterious effects due to Cd exposure. Cd-induced testicular toxicity is mediated through oxidative stress, inflammation, testosterone inhibition and apoptosis. Thus, the present study was performed to assess the possible protective role of infliximab (IFX), anti-TNFα agent, against Cd-induced testicular damage and spermiotoxicity in rats. The rats were randomly allotted into six experimental groups: control, Cd sulphate treated, Cd sulphate treated with infliximab (5 mg/kg), Cd sulphate with infliximab (7 mg/kg), infliximab alone (5 mg/kg), and infliximab alone (7 mg/kg). The control group received saline. To induce testicular damage, Cd sulphate (1.5 mg/100 gm body weight/day) was dissolved in normal saline and orally administrated for 3 consecutive weeks. The rats in infliximab-treated groups were given a weekly dose of 5 mg/kg/week or 7 mg/kg/week of infliximab intraperitoneally. In the current study Cd exposure reduced sperm count, markers of testicular function, sperm motility as well as gene expression of testicular 3β-HSD and 17β-HSD and serum testosterone level. Additionally, it increased testicular oxidative stress, inflammatory and apoptotic markers. The histopathologic studies supported the biochemical findings. Treatment with infliximab significantly attenuated Cd-induced injury verified by the restoration of testicular architecture, enhancement of steroidogenesis, preservation of spermatogenesis, modulation of the inflammatory reaction along with suppression of oxidative stress and apoptosis. It was concluded that infliximab, through its antioxidant, anti-inflammatory and anti-apoptotic effects, represents a potential therapeutic option to protect the testicular tissue from the detrimental effects of Cd.
Identifiants
pubmed: 31276887
pii: S0147-6513(19)30719-5
doi: 10.1016/j.ecoenv.2019.109398
pii:
doi:
Substances chimiques
Antioxidants
0
Protective Agents
0
TNF protein, human
0
Tumor Necrosis Factor-alpha
0
Cadmium
00BH33GNGH
Testosterone
3XMK78S47O
Infliximab
B72HH48FLU
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
109398Informations de copyright
Copyright © 2019 Elsevier Inc. All rights reserved.